1. Introduction {#sec1}
===============

Hyperpigmentary skin disorders are a major issue of concern for people with dark skin. Until now, clinicians have attempted to treat hyperpigmentary disorders using various therapeutic modalities, including hypopigmenting agents, but the results have been discouraging.

Diverse types of immune cells have been thought to play an important role in melanogenesis. Various inflammatory dermatoses can induce postinflammatory hyperpigmentation by affecting the morphologic change and functional activity of melanocyte. We recently reported the inflammatory features of melasma in Korean women and that mast cells are frequently found in the dermis of melasma lesions \[[@B1]\]. In addition, we proposed the association between increased dermal mast cells and clinical features of hyperpigmentation and telangiectasia in photodamaging process \[[@B2]\]. Therefore, inflammatory mediators such as histamine, prostaglandins, and nitric oxide have been identified as possible therapeutic approaches for hyperpigmentary skin disorders \[[@B3]\].

Histamine is a ubiquitously distributed inflammatory mediator that is released from tissue mast cells and blood basophils, thereby inducing various inflammatory skin disorders. Since the cutaneous actions of histamine as a melanogen were first reported \[[@B4]\], there have been studies on the role of histamine in skin hyperpigmentation \[[@B3], [@B5], [@B6]\]. Histamine-induced morphologic changes in human melanocytes and increased tyrosinase activity, resulting in increased melanogenesis and H~2~ antihistamines specifically, suppressed the stimulatory effects of histamine \[[@B5], [@B6]\]. However, the involvement of histamine in melanogenesis via other receptors such as H~1~, H~3~, and H~4~ receptors remains unclear. Especially considering common use of H~1~ antihistamines in dermatologic practice, it is remarkable that little has been reported about the effects of H~1~ antihistamines on melanogenesis. Therefore, we tried to focus for defining the effects of H~1~ antihistamines on melanogenesis.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Loratadine, 3,4-dihydroxy-L-phenylalanine (L-DOPA), cholera toxin (CT), 12-O-tetradecanoylphorbol-13-acetate (TPA), and antibodies specific to *β*-actin were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Antibody specific for Akt (\#2920S), phosphor-Akt (ser473, \#4058S), *β*-catenin (\#9562L), GSK-3*β* (27C10, \#9315), phospho-GSK-3*β* (Ser9, \#9336), p44/42 MAPK (Erk1/2) (\#9102S), and p44/42 MAPK (Erk1/2) (Thr202/Tyr204, \#9101S) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies specific for tyrosinase (C-19) and PKC-*β*II (C-18) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Microphthalmia (MITF) Ab-1 (C5, MS-771-P0) was obtained from Neomarkers (Fremont, CA, USA).

2.2. Cell Culture {#sec2.2}
-----------------

Normal human melanocytes (NHM) were obtained from Invitrogen and maintained in Medium 254 (Cascade Biologics, Portland, OR, USA), which contained human melanocyte growth supplement at 37°C in a 5% CO~2~ incubation \[[@B7]\]. The Mel-Ab cell line is a mouse-derived, spontaneously immortalized melanocyte cell line that synthesizes large quantities of melanin. Mel-Ab cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 nM TPA, 1 nM CT, 1% antibiotic-antimycotic solution (100X) at 37°C in 5% CO~2~. B16F10 cells were maintained in DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic solution (100X) at 37°C in 5% CO~2~ \[[@B8]\].

2.3. Cell Viability Assay {#sec2.3}
-------------------------

Cell viability of NHM and Mel-Ab cells was measured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Duchefa, Netherlands) assay. NHM and Mel-Ab cells were seeded at the same density in 24-well plate. After incubation with loratadine for 24 hr. MTT was prepared as 2.5 mg/ml stock solution in phosphate buffered saline (PBS) and stored at 4°C. Then, stock MTT solution was added at 200 *μ*l/well and the plates incubated at 37°C for 30 min to 4 hr. Thereafter, MTT solution was removed. After addition of 3 ml of DMSO the plates were incubated for 15 min at 37°C to dissolve the formazan crystals. Absorbance was measured at 570 nm using an enzyme immunosorbent assay (ELISA) reader (Molecular Devices Co., Sunnyvale, CA). The reference wavelength was 560-650 nm.

2.4. Melanin Contents and Microscopy {#sec2.4}
------------------------------------

NHM and Mel-Ab cells were treated with specific agonists and for 5 days or 3 days. Cells were dissolved in 550 *μ*l of 1 N NaOH at 100°C for 30 min and centrifuged at 13,000 rpm for 5 min. The optical density (OD) of the supernatants was measured at 405 nm using a microplate reader. Before measuring the melanin content, the cells were observed under a phase contrast and photographed for microscope (Olympus, Tokyo, Japan).

2.5. Tyrosinase Activity {#sec2.5}
------------------------

NHM and Mel-Ab cells were seeded in 6-well plates and incubated with loratadine for 5 days or 3 days. The cells were washed with ice-cold PBS and lysed with phosphate buffer (pH 6.8) containing 1% Triton X-100. The cells were then disrupted by freezing and thawing, and the lysates were clarified by centrifugation at 15000 rpm for 10 minutes. After quantifying the protein levels of the lysate and adjusting the protein concentrations with lysis buffer, 90 *μ*l of each lysate containing the same amount of protein was placed in each well of a 96-well plate, and 10 *μ*l of 10 mM L-DOPA was then added to each well. The control wells contained 90 *μ*l of lysis buffer and 10 *μ*l of 10 mM L-DOPA. Following incubation at 37°C, absorbance was measured every 10 min for at least 1 hr at 475 nm using a microplate reader.

2.6. Cell Fractionation {#sec2.6}
-----------------------

We used a cell fractionation kit from cell signaling. Cell fractionation was performed according to the manufacturer\'s instructions.

2.7. Western Blot Analysis {#sec2.7}
--------------------------

Cells were lysed in protein lysis buffer and centrifuged at 13,000 rpm for 30 min. The protein concentration was determined using a Bradford protein assay. 20 *μ*g of protein per lane was separated by SDS-polyacrylamide gel electrophoresis and blotted onto nitrocellulose membranes, which were then saturated with 5% skim milk in Tris-buffered saline containing 0.5% Tween 20. Blots were incubated with the appropriate primary antibodies following the manufacturer\'s data sheet. Image analysis was used to determine the relative band densities, which was performed using Image J software (<https://imagej.nih.gov/ij/>).

2.8. Total RNA Extraction and cDNA Synthesis {#sec2.8}
--------------------------------------------

Total cellular RNA was extracted from the NHM using the Favor Prep™ Total RNA purification mini according to the manufacturer\'s instructions (Favorgen, Ping Tung, Taiwan). Following isolation, the quantity and quality of the RNA were determined using a NanoDrop ND-1000 spectrophotometer (ND-1000, NanoDrop Technologies, Inc. Wilmington, DE, USA). Single-stranded complementary DNA (cDNA) was synthesized from 1 *μ*g of total RNA using RevertAid First Strand cDNA Synthesis kit according to the manufacturer\'s instructions (Thermo Scientific, Rockford, IL, USA).

2.9. Real-Time RT-PCR {#sec2.9}
---------------------

qRT-PCR was performed using the LightCycler® 480II machine coupled with SYBR Green chemistry (Roche Applied Science, Indianapolis, IN, USA). In terms of qRT-PCR settings, initial denaturation was performed at 95°C for 5 min, followed by amplification at 95°C for 10 sec, 60°C for 10 sec, and 72°C for 10 sec for 45 cycles. The cDNA obtained was amplified with the following primers: RPLP0, Forward 5′-GGCGACCTGGAAGTCCAACT-3′, Reverse 5′-CCATCAGCACCACAGCCTTC-3′. MITF, Forward 5′-ACTTTCCCTTATCCCATCCACC-3′, Reverse 5′-TGAGATCCAGAGTTGTCGTACA-3′. Primers specific for RPLP0 were used for loading control amplifications.

2.10. Statistics {#sec2.10}
----------------

The statistical significance of the differences between groups was assessed using analysis of variance (ANOVA), followed by the Student\'s*t*-test. In this study,*p* \<0.05 is considered significant.

3. Results {#sec3}
==========

3.1. Loratadine, an H1- Receptor Antagonist, Suppresses Melanogenesis in NHM and Mel-Ab Cells {#sec3.1}
---------------------------------------------------------------------------------------------

Even though H2-receptor agonists and antagonists have been extensively studied previously, the effect of H1-receptor antagonists on melanogenesis has not been fully understood. First, we explored whether H1-receptor antagonists influenced the melanogenesis in B16F10 cells. Among the H1-receptor antagonists screened, ebastine, clemisole, terfenadine, and loratadine significantly decreased the melanin content ([Table 1](#tab1){ref-type="table"} and Supplementary Fig. [1A](#supplementary-material-1){ref-type="supplementary-material"}). We selected ebastine and loratadine as they decreased the melanin content in a dose-dependent manner. While ebastine affected cellular viability in NHM and Mel-Ab cells (data was not shown), loratadine showed a dose-dependent response without affecting cellular viability in NHM and Mel-Ab cells (Figures [1(a)](#fig1){ref-type="fig"} and [1(c)](#fig1){ref-type="fig"}). Also, loratadine treatment decreased the tyrosinase activity in a dose-dependent manner ([Figure 1(b)](#fig1){ref-type="fig"}).

To determine the involvement of H1-receptor agonist on melanogenesis, we evaluated the effects of 2-pyridylethylamine, an H1-receptor agonist. The H1 receptor agonist did not affect the melanin content in Mel-Ab cells or reverse the loratadine induced melanin reduction (Supplementary [Figure 1B](#supplementary-material-1){ref-type="supplementary-material"} and [1C](#supplementary-material-1){ref-type="supplementary-material"}).

3.2. Loratadine Inhibits Expression Levels of MITF in NHM {#sec3.2}
---------------------------------------------------------

As loratadine decreased melanin synthesis and tyrosinase activity, we next determined whether loratadine affected the expression of MITF, which plays crucial role in tyrosinase gene expression in melanogenesis. Loratadine significantly decreased the protein level of MITF and tyrosinase at 12 hr ([Figure 2(a)](#fig2){ref-type="fig"}). Furthermore, MITF and tyrosinase mRNA level also decreased after loratadine treatment ([Figure 2(b)](#fig2){ref-type="fig"}). These results indicated that loratadine reduced melanogenesis through the downregulation of MITF signaling pathway.

3.3. Inhibitory Effects of Loratadine on Melanogenesis Were Partially Associated with Akt Phosphorylation in NHM {#sec3.3}
----------------------------------------------------------------------------------------------------------------

To investigate the intracellular signaling pathways, expression levels of *β*-catenin, phospho-GSK-3*β*, phospho-Akt, and phospho-ERK were detected in NHM ([Figure 3(a)](#fig3){ref-type="fig"}). To determine the effect of loratadine on PI3K/Akt/GSK-3*β* signaling pathway, phosphorylation of Akt and GSK-3*β* was found to be increased following loratadine treatment, markedly at 30 min. *β*-catenin and phospho-ERK were not altered.

We next evaluated whether LY294002, a selective inhibitor of PI3K, affected the inhibitory effect of loratadine on melanogenesis. As shown in [Figure 3(b)](#fig3){ref-type="fig"}, loratadine monotreatment significantly reduced the melanin content, whereas cotreatment with LY294002 and loratadine reversely increased the melanin content in NHM. Our results revealed that antimelanogenic effect of loratadine in NHM is associated with activation of PI3K/Akt/GSK-3*β* signaling pathway.

3.4. Antimelanogenic Effects of Loratadine Were Associated with Membrane PKC-*β*II in NHM {#sec3.4}
-----------------------------------------------------------------------------------------

H1-receptor is one of the G protein-coupled receptors that couples to G*α*~q/11~ proteins, leading to the activation of the calcium/protein kinase C (PKC) pathway. Since, specifically, PKC-*β*II is activator of tyrosinase, we investigated whether loratadine could decrease activity of PKC-*β*II. As shown in [Figure 3(c)](#fig3){ref-type="fig"}, loratadine treatment reduced the amount of PKC-*β*II in the membrane fraction, thereby decreasing its activity. The molecular mechanisms of antimelanogenic effect of loratadine demonstrated above are summarized in [Figure 4](#fig4){ref-type="fig"}.

4. Discussion {#sec4}
=============

Histamine acts through 4 different classes of receptors (H~1~, H~2~, H~3~, and H~4~ receptors) on effector cells. Among these 4 receptors, H~1~ and H~2~ receptors have been extensively studied and demonstrated well-known proallergic properties \[[@B9]\]. Since the first synthesized in 1937, H~1~ antihistamines have been some of the most commonly prescribed medicine in dermatologic conditions, including allergic reactions, urticaria, atopic dermatitis, and pruritus. Antihistamines were considered histamine receptor antagonists, but they actually work as inverse agonists by binding to histamine receptors, thereby returning cellular equilibrium and reducing allergic property \[[@B10]\].

Moreover, H~1~ and H~2~ receptors exist on the surface of human melanocytes and melanoma cells \[[@B11]\]. Yoshida et al. \[[@B6]\] have reported that histamine induces melanogenetic effects on human melanocytes by accumulating cyclic adenosine monophosphate (cAMP) and subsequently activating protein kinase A (PKA), especially via the H~2~ receptor. Kim et al. \[[@B12]\] investigated the signaling pathways involved in histamine-induced melanocyte proliferation and melanogenesis. They showed that an H~2~ antihistamine, famotidine, suppressed the effects induced by the H~2~ agonist, amthamine, and histamine itself. Histamine stimulated melanocyte proliferation and melanogenesis via the H~2~ receptor and Erk, CREB, or Akt activation \[[@B12]\]. More recently, it was reported that the H~2~ receptor mediated growth-differentiation factor-15 (GDF-15) could be involved in histamine-induced melanogenesis \[[@B13]\]. In an*in vivo* study, the UVB-induced hyperpigmentation of guinea pig skin was suppressed by topically applying an H~2~ antihistamine \[[@B14]\].

Although the H~1~ receptor is a major therapeutic target of inflammatory skin disorders, there have been few studies about melanogenesis of H~1~ antihistamine \[[@B6], [@B15]\]. For example, mepyramine, an H~1~ antihistamine, did not inhibit melanogenesis that is induced by histamine \[[@B6]\]. Therefore, first we screened antimelanogenic effects by H~1~ antihistamines using LOPAC chemical library ([Table 1](#tab1){ref-type="table"}). Among them, ebastine, clemisole, terfenadine, and loratadine significantly decreased the melanin content, but loratadine was ultimately selected as its dose-dependent linear hit without affecting cellular viability. Our study found that H~1~ antihistamine, especially loratadine, demonstrates obvious antimelanogenic effects in NHM. Loratadine led to the significant inhibition of mRNA and protein expression level of MITF, which in turn suppressed tyrosinase, a key enzyme that controls melanogenesis.

Akt activation has been reported to reduce melanogenesis via transcriptional downregulation of MITF gene expression \[[@B16]\]. Furthermore, in other mechanism, PI3K/Akt/GSK-3*β* signaling pathway regulates posttranslational modification and proteasomal degradation of MITF protein \[[@B17]\]. In our present study, loratadine suppressed the MITF mRNA expression in NHM, which reversely increased after inhibition of Akt pathway by the selective inhibitor of PI3K, LY294002. Therefore, antimelanogenic effects of loratadine in NHM are shown to be related to activation of PI3K/Akt/GSK-3*β* signaling and the subsequent decrease in the MITF mRNA level.

Unlike H~2~ receptor, which is bound to G~as~ protein and regulates melanogenesis via cAMP/PKA/CREB signaling pathway, H~1~ receptor mainly acts by coupling G~aq/11~ proteins, which in turn activate inositol trisphosphate (IP~3~)/diacylglycerol (DAG) pathway and subsequently localizing PKC enzymes to membrane \[[@B9]\]. PKC-*β*II, a regulator of tyrosinase activity, especially, is known to increase melanogenesis and the activity of PKC-*β*II is determined by the membrane localization \[[@B18]\]. As expected, loratadine did not affect the phosphorylation of CREB, but reduced activity of PKC-*β*II.

Our study had several limitations. Although loratadine showed the antimelanogenic effect at the cellular level, these results do not always provide the same outcomes as a clinical manner. Therefore, for practical application of the results, further clinical studies will be required to determine the therapeutic regimen of loratadine for treatment of hyperpigmentary disorders in humans.

Taken together, we demonstrated strong antimelanogenic effect of H~1~ antihistamine, loratadine via modulating Akt/MITF, and PKC-*β*II signaling. Considering common use of H~1~ antihistamines in dermatologic practice, the antimelanogenic effects of loratadine may have potentially significant and useful roles. Although further clinical studies will be needed, loratadine may give benefits for treatment of hyperpigmentary changes accompanied by various types of dermatitis.
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###### 

Supplementary Figure 1: effects of H1-receptor agonist and antagonists on melanogenesis. Supplementary Figure 2: effects of loratadine on cellular viability in normal human melanocytes.

###### 

Click here for additional data file.

![Effects of H~1~ antihistamine, loratadine, on melanogenesis in normal human melanocytes (NHM) and Mel-Ab cells. (a) NHM and Mel-Ab cells were cultured with 1.0-7.5 *μ*M loratadine for 5 days and 4 days each and compared with 100 *μ*g/ml arbutin. The cell images were taken using phase contrast microscopy, and the decrease in melanin is evident. (b) Loratadine suppressed tyrosinase activity in NHM and Mel-Ab cells. NHM and Mel-Ab cells were incubated with 1.0-7.5 *μ*M loratadine for 5 days and 4 days each, and the cellular tyrosinase activity was then measured. Arbutin (100 *μ*g/ml) was used as a positive control. Each determination was made in triplicate, and the data represent the mean ± SD. ^*∗*^p \< 0.05 and ^*∗∗*^p \< 0.01 in comparison with the untreated control. (c) The viability of NHM and Mel-Ab cells was not affected by treatment with 1.0-7.5 *μ*M loratadine for 24 hr. Cell viability was determined using MTT assay. Each measurement was made in triplicate.](BMRI2019-5971546.001){#fig1}

![Inhibitory effect of loratadine on mRNA and protein expression of MITF and tyrosinase. (a) Loratadine dramatically decreased the mRNA levels of MITF after 4 hr. (b) Loratadine reduced the protein levels of MITF and tyrosinase. NHM were incubated with 7.5 *μ*M loratadine at indicated time. Whole-cell lysates were then analyzed by western blotting using antibodies against MITF and tyrosinase. Normalization was achieved by dividing the values for individual bands by the densitometry values for *β*-actin in the same lane. The value of densitometry was graphed with the mean ± SD. ^*∗*^p \< 0.05.](BMRI2019-5971546.002){#fig2}

![The effects of loratadine on melanogenesis-related signaling pathways. After excluding the influence of PMA by 3 hr starvation, NHM were treated with 7.5 *μ*M loratadine for the indicated times. (a) Whole-cell lysates were analyzed by western blot using antibodies, *β*-catenin, phospho-Erk, phospho-Akt, and phospho-GSK-3*β*, and equal protein loading was confirmed by the *β*-actin levels. Phospho-Akt and phospho-GSK-3*β* were consistently elevated by loratadine. (b) LY294002, a selective inhibitor of PI3K, could reverse the increase of phospho-Akt in loratadine treated NHM. (c) Loratadine treatment reduced the amount of PKC-*β*II in the membrane fraction, thereby decreasing its activity.](BMRI2019-5971546.003){#fig3}

![Antimelanogenic effect of H~1~ antihistamine, loratadine via modulating Akt/MITF, and PKC-*β*II signaling.](BMRI2019-5971546.004){#fig4}

###### 

Summary of the H1 antihistamines screened for antimelanogenesis. Among them, clemisole, ebastine, loratadine, and terfenadine significantly decreased the melanin content (text with *∗*).

  Name                               Trade name                                                                          Therapeutic chemical class      Systematic (IUPAC) name                                                                                        Molecular weight
  ---------------------------------- ----------------------------------------------------------------------------------- ------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------
  First generation antihistamines                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                        
  Brompheniramine maleate            Bromfed, Dimetapp, Bromfenex, Dimetane, Lodrane                                     Alkylamine                      3-(4-bromophenyl)-*N*,*N*-dimethyl-3-pyridin-2-yl-propan-1-amine                                               435.3213
  Chlorpheniramine maleate           Chlor-trimeton                                                                      Alkylamine                      3-(4-chlorophenyl)-*N*,*N*-dimethyl-3-pyridin-2-yl-propan-1-amine                                              390.8703
  Clemastine fumarate                Tavist                                                                              Aminoalkyl ethers               (2*R*)-2-{2-\[(1*R*)-1-(4-chlorophenyl)-1-phenylethoxy\]ethyl}-1-methylpyrrolidine                             459.9746
  Clemizole hydrochloride^**∗**^     \-                                                                                  \-                              1-\[(4-chlorophenyl)methyl\]-2-(pyrrolidin-1-ylmethyl)benzimidazole                                            362.3053
  Diphenhydramine hydrochloride      Benadryl, unisom, sominex, zzzquil                                                  Aminoalkyl ethers               2-(diphenylmethoxy)-*N*,*N*-dimethylethanamine                                                                 291.824
  Doxylamine succinate               unisom                                                                              Aminoalkyl ethers               *(RS*)-*N*,*N*-dimethyl-2-(1-phenyl-1-pyridin-2-yl-ethoxy)-ethanamine                                          388.4677
  Methapyrilene hydrochloride        \-                                                                                  Substituted ethylenediamines    *N*,*N*-dimethyl-*N*′-pyridin-2-yl-*N*′-(2-thienylmethyl)ethane-1,2-diamine                                    297.8526
  Orphenadrine hydrochloride         Norflex, Banflex, Orphenate, Flexoject, Flexon                                      Aminoalkyl ethers               *N*,*N*-dimethyl-2-\[(2-methylphenyl)- phenyl-methoxy\]-ethanamine                                             305.8511
  Pheniramine maleate                Avil                                                                                Substituted alkylamines         *N*,*N*-dimethyl-3-phenyl-3-pyridin-2-yl-propan-1-amine                                                        356.4253
  Promethazine hydrochloride         Phenergan                                                                           Phenothiazine derivatives       *(RS*)-*N,N*-dimethyl-1-(10*H*-phenothiazin-10-yl)propan-2-amine                                               320.8873
  Pyrilamine maleate                 Pyrlex                                                                              Substituted ethylene diamines   *N*-(4-methoxybenzyl)-*N*′,*N*′-dimethyl-*N*-pyridin-2-ylethane-1,2-diamine                                    401.4664
  Triprolidine hydrochloride         Actidil, Myidil, Actifed                                                            other                           2-\[(*E*)-1-(4-methylphenyl)-3-pyrrolidin-1-yl- prop-1-enyl\]pyridine                                          314.8616
                                                                                                                                                                                                                                                                        
  Second generation antihistamines                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                        
  Ebastine^**∗**^                    Evastin, kestine, ebastel, aleva, ebatrol                                           Other                           4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)butan-1-one                                              469.6731
  Cetirizine dihydrochloride         Zirtec, Zyrtec, reactine                                                            Piperazine derivatives          (±)-\[2-\[4-\[(4-chlorophenyl)phenylmethyl\]-1- piperazinyl\]ethoxy\]acetic acid                               461.8199
  Epinastine hydrochloride           Alesion, Elestat, Purivist, Relestat                                                other                           (*RS*)-3-amino-9,13b-dihydro-1*H*-dibenz(c,f)imidazo(1,5-a)azepine                                             285.779
  Ketotifen fumarate                 Zaditor                                                                             other                           4-(1-Methylpiperidin-4-ylidene)-4,9-dihydro-10*H*-benzo\[4,5\]cyclohepta\[1,2-*b*\]thiophen-10-one             425.5075
  Loratadine^**∗**^                  Claritin, Claratyne                                                                 other                           Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo\[5,6\]cyclohepta\[1,2-b\]pyridin-11-ylidene)-1-piperidinecarboxylate   382.8938
  Terfenadine^**∗**^                 Seldane, Triludan, Teldane                                                          other                           (*RS*)-1-(4-*tert*-butylphenyl)-4-{4-\[hydroxy(diphenyl)methyl\]piperidin-1-yl}-butan-1-ol                     471.6891
                                                                                                                                                                                                                                                                        
  Third generation antihistamine                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                        
  Fexofenadine hydrochloride         Allegra, Fexidine, Telfast, Fastofen, Tilfur, Vifas, Telfexo, Allerfexo, Flexofen   other                           (±)-4-\[1-Hydroxy-4-\[4-(hydroxydiphenylmethyl)-1-piperidinyl\]-butyl\]-*α*, *α*-dimethyl benzeneacetic acid   501.6719
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